The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.

Sponsor
Tanta University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04554589
Collaborator
(none)
80
1
2
6.8
11.7

Study Details

Study Description

Brief Summary

Tracheostomized patients in the ICU can have excessive tracheal secretions due to various causes as hyperactive airway, irritation of the mucus producing cells and inhibition of the ciliary functions. Excessive secretions will necessitate frequent suctions which carries the risk of tracheostomy tube obstruction if not managed properly. Excessive tracheal secretions may prolong the ICU stay, increase the nurses workload and increase patients morbidity and mortality.

This clinical trial hypothesizes that the use of glycopyrrolate may decrease the tracheal secretions and hence avoid such complications.

Condition or Disease Intervention/Treatment Phase
  • Drug: Glycopyrrolate 0.2 MG
  • Drug: normal saline
Phase 1

Detailed Description

Patients fulfilling the inclusion criteria will be randomly assigned into one of 2 groups:

Group G (Intervention group): Patients will receive Glycopyrrolate 0.2 mg IV every 8 hours.

Group C (Control group): Patients will receive 2 mL Normal saline every 8 hours.

Both injections will be labelled as drug A and drug B in the satellite pharmacy .

Both the attending physician, nurse and data collector will be blinded to the injection given.

Measurements data will be collected and recorded daily in the pre-prepared CRF during the study period.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.
Anticipated Study Start Date :
Sep 14, 2020
Anticipated Primary Completion Date :
Feb 10, 2021
Anticipated Study Completion Date :
Apr 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: intervention group

receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .

Drug: Glycopyrrolate 0.2 MG
injections
Other Names:
  • Glycopyrronium Injection
  • Placebo Comparator: placebo group

    receive normal saline 2 ml IV every 8 hours daily .

    Drug: normal saline
    normal saline

    Outcome Measures

    Primary Outcome Measures

    1. Number of suctions per day [6 days]

      Number of suctions per day

    Secondary Outcome Measures

    1. The duration of ICU days [90 days]

      the total days the patient will spend in ICU

    2. Fio2 [6 days]

      Fio2 on mechanical ventilation every 4 hours daily

    3. Mean airway pressure [6 days]

      Mean airway pressure will be recorded every 4 hours on the mechanical ventilator

    4. Positive end expiatory pressure PEEP [6 days]

      PEEP will be recorded every 4 hours on the mechanical ventilator

    5. The duration of mechanical ventilation days [90 days]

      Total days spent on mechanical ventilation

    6. Side effects of Glycopyrrolate [6 days]

      Episodes of tachycardia if heart rate reach 120 beats / minute

    7. Fluid intake [6 days]

      Fluid balance calculated daily

    8. Total leukocyte count [6 days]

      Total leukocyte count daily

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients above 18 years old.

    2. Patients who are admitted to ICU for more than 72 hours.

    3. Patients who have tracheostomy tubes with reported frequent need for suction of the tracheostomy tube secretions more than once every 4 hours.

    Exclusion Criteria:
    1. Patients who have evidence of lower respiratory tract infections and have positive cultures from the tracheal aspirate.

    2. Patients who have known sensitivity to Glycopyrrolate.

    3. Patients who have tachycardia (heart rate above 120 Beats/minute) or known to have tachyarrhythmiase.g atrial fibrillation.

    4. Patients with mitral stenosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Security Forces Hospital Riyadh Saudi Arabia

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: Mohammed Abosamak, MD, health care provider

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    MOHAMMED FAWZI ALI ABOSAMAK, ICU consultant, Tanta University
    ClinicalTrials.gov Identifier:
    NCT04554589
    Other Study ID Numbers:
    • 0000-0002-141
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Sep 23, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 23, 2020